EcoR1 Puts Up Big Gains as the Hedge Fund Scoops Up Biotech
EcoR1’s main hedge fund has produced big, double-digit gains in 2019, according to a document obtained by Institutional Investor.
EcoR1 Capital is on a buying spree of beaten-down, biotechnology companies as it nears the end of 2019 with big returns.
In November, the hedge fund firm established sizable stakes in Pieris Pharmaceuticals, AnaptysBio, and X4 Pharmaceuticals, according to regulatory filings. This month, the firm won a board seat in its activist bet targeting Prothena Corp.,